


Coronary Vascular Disorders

Dr. Rexi Thomas

Atherosclerosis- Pathophysiology

- Injury to vascular endothelium
 - Smoking
 - HTN
 - Other
- Narrowing of lumen
- Rupture plaque
 - ACS
 - MI



Risk Factors for CAD

Non-modifiable

- Family hx
- Age
- Gender
- Race


Modifiable

- HTN
- Smoking
- Hyperlipidemia (↑ cholesterol, LDL, ↓ HDL)
- Metabolic syndrome
- DM
- Obesity
- ↓ Physical activity

Metabolic Syndrome

- 3 of the following:
 - Insulin resistance
 - Central obesity
 - Dyslipidemia
 - BP > 130/85 mmHg
 - Proinflammatory states (C-reactive protein)
 - Prothrombic state

Physiology/Pathophysiology



CAD Prevention

- 4 modifiable risk factors
- Cholesterol
 - Fasting lipid profile every 5 yrs (≥ age 20)
 - Dietary changes
 - Physical activity
 - Medications (HMG-CoA reductase inhibitors, nicotinic acid, fibric acids, bile acid sequestrants, cholesterol absorption inhibitors, omega 3 acid)
- Cessation of smoking
- Manage HTN

Angina Pectoris

- Pathophysiology
- Types
 - Stable angina
 - Unstable angina (preinfarction or crescendo angina)
 - Intractable/ Refractory
 - Variant angina (Prinzmetal)
 - Silent ischemia
- Assessment- S/S

Angina Pectoris


- Diagnostics
 - ECG
 - CRP
 - Stress test
 - Cardiac catheterization/ angiography

Angina Pectoris

- Treatment/ Management
 - Medication
 - Nitroglycerin
 - Beta-Adrenergic
 - Metoprolol, Atenolol
 - Calcium channel blockers
 - Antiplatelet/ Anticoagulants
 - ASA, plavix, heparin, glycoprotein IIb/ IIIa
 - Oxygen

Acute Coronary Syndrome (ACS)

- Unstable angina
- Non- ST segment elevation MI (NSTEMI)
- ST- segment elevation MI (STEMI)




Assessment of ACS/ MI

- Cardiovascular
 - Chest pain, murmur, bp, pulse, ECG
- Respiratory
 - SOB, dyspnea, tachypnea, crackles
- GI/ GU
 - Nausea, vomiting, ↓ urine output
- Skin
 - Cool, clammy, diaphoretic, pallor
- Neurological
 - Anxiety, restlessness, lightheadedness

Diagnostic/ Laboratory Test

- ECG
- CXR
CRP
- Cardiac enzymes/ markers
 - Creatine kinase (CK-MB)
 - Myoglobin
 - Troponin

Time Course of Enzyme Markers




Management/ Treatment

- Goal is reperfusion
- Decrease myocardial damage

- Rapid transfer to hospital
- ECG within 10 minutes of arrival to ED
- Diagnostics/ lab tests
- Interventions
 - Oxygen
 - Nitroglycerin
 - Morphine
 - ASA
 - Beta blocker
 - ACE (within 24 hrs)
 - Anticoagulation with heparin and platelet inhibitors
- Evaluation for indications of reperfusion
 - Percutaneous coronary intervention (PCI) within 60 minutes
 - Thrombolytic therapy (t-PA/ r-PA within 30 minutes- alteplase/ reteplase)
- Continuous therapy as indicated
 - IV heparin
 - Plavix
 - Glycoprotein inhibitor
 - Bedrest minimum 12 to 24 hours


Percutaneous Coronary Interventions (PCI)

- Percutaneous Transluminal Coronary Angioplasty
- Coronary artery stent
- Atherectomy
- Brachytherapy





Coronary Artery Revascularization

- Traditional coronary artery bypass graft (CABG)



Cardiopulmonary Bypass





Complications of Cardiac Surgery

- ↓ Cardiac output
 - Hypovolemia, bleeding, cardiac tamponade, fluid overload, hypothermia, HTN, tachydysrhythmias, bradycardia, cardiac failure, MI
- Pulmonary
 - Impaired gas exchange
- Neurological
 - CVA
- Renal/ Electrolyte
 - Acute renal failure (ARF), electrolyte imbalance
- Other
 - Hepatic failure, infection

Cardiac Rehabilitation

- Phase I
 - Dx of atherosclerosis
 - Unstable angina, MI
- Phase II
 - After discharge from hospital
 - 3x a week x 4-6 weeks
- Phase III
 - Long-term outpatient
